Mitochondrial Permeability Transition Pore (mPTP) in Neurodegeneration describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders. [1]
The mitochondrial permeability transition pore (mPTP) is a non-specific channel that forms across the inner mitochondrial membrane under conditions of calcium overload, oxidative stress, or adenine nucleotide depletion 1. When the mPTP opens, the mitochondrial membrane potential dissipates, ATP production ceases, and cells undergo programmed necrosis or apoptosis 2. In neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), chronic mPTP opening contributes to neuronal death through bioenergetic failure, ROS release, and cytochrome c efflux 3. [2]
The molecular identity of the mPTP remains incompletely resolved, but key components have been identified: [3]
| Component | Function | Evidence | [4]
|-----------|----------|----------| [5]
| VDAC (VDAC1) | Outer membrane channel | Direct interaction with HKII 4 | [6]
| ANT (ANT1/ANT2/ANT3) | Inner membrane transporter | Cyclophilin D binding 5 | [7]
| Cyclophilin D (Ppif) | Peptidyl-prolyl isomerase | Genetic knockout blocks mPTP 6 | [8]
| mitochondrial phosphate carrier (PiC) | Phosphate transport | Essential for pore opening 7 | [9]
| Sp1 transcription factor | Regulates VDAC expression | Links to calcium signaling 8 | [10]
| F1F0-ATP synthase (ATP5A1) | May form pore core | Recent structural studies 9 | [11]
The primary triggers for mPTP opening are: [12]
Amyloid-β (Aβ) peptides directly induce mPTP opening in several ways: [13]
Hyperphosphorylated tau disrupts mitochondrial dynamics and sensitizes neurons to mPTP opening: [14]
| Strategy | Mechanism | Status | [15]
|----------|-----------|--------| [16]
| Cyclosporine A | Inhibit cyclophilin D | Neuroprotective in models 21 | [17]
| NIM811 | Non-immunosuppressive CsA analog | Preclinical 22 | [18]
| VDAC1 blockers | Prevent Aβ-VDAC interaction | Early development 23 | [19]
| Mitochondrial antioxidants | Reduce ROS | Clinical trials 24 | [20]
PD is strongly associated with mitochondrial complex I deficiency: [21]
α-Synuclein aggregation impacts mPTP through multiple mechanisms: [22]
| Gene | Function | mPTP Connection | [23]
|------|----------|-----------------| [24]
| PARK7 (DJ-1) | Mitochondrial protection | Antioxidant function; loss increases ROS and mPTP sensitivity 31 | [25]
| PARK6 (PINK1) | Mitophagy kinase | Loss leads to accumulation of damaged mitochondria prone to mPTP 32 | [26]
| PARK2 (Parkin) | E3 ligase | Mitophagy of mPTP-prone mitochondria 33 | [27]
In ALS, astrocytes release factors that sensitize motor neurons to mPTP: [28]
Motor neurons have high energy demands and are particularly vulnerable to mPTP: [29]
Mutant huntingtin (mHtt) directly disrupts mitochondrial function: [30]
| Marker | Disease | Interpretation | [31]
|--------|---------|---------------| [32]
| Cytochrome c in plasma | AD, PD | Indicates mPTP-mediated cell death 46 | [33]
| mtDNA in CSF | ALS | Released from dying mitochondria 47 | [34]
| Caspase-3 activation | AD | Downstream of mPTP 48 | [35]
| Lactate/pyruvate ratio | All ND | Oxidative phosphorylation failure 49 | [36]
The mPTP represents a final common pathway for neuronal death in neurodegenerative diseases. While its molecular identity remains incompletely resolved, therapeutic strategies targeting mPTP components show promise in preclinical models. The challenge lies in developing agents that can cross the blood-brain barrier and specifically modulate mPTP opening without disrupting normal mitochondrial function. [37]
Additional evidence sources: [38] [39] [40] [41]
Halestrap et al. ROS and mPTP (2002). 2002. ↩︎
Khatri et al. Aβ42 and VDAC (2012). 2012. ↩︎
Michikawa et al. Aβ and calcium (2003). 2003. ↩︎
Abramov et al. Aβ and ROS (2007). 2007. ↩︎
Du et al. Cyclophilin D in AD (2008). 2008. ↩︎
Thinakaran et al. Tau and VDAC (2010). 2010. ↩︎
Kerr et al. Drp1 in AD (2010). 2010. ↩︎
Baines et al. Cyclosporine A neuroprotection (2002). 2002. ↩︎
Waldmeier et al. NIM811 in AD (2003). 2003. ↩︎
Liu et al. Mitochondrial antioxidants (2011). 2011. ↩︎
Gambello et al. PINK1/Parkin in PD (2011). 2011. ↩︎
Sharon et al. α-Synuclein and mitochondria (2011). 2011. ↩︎
Calore et al. α-Synuclein and calcium (2015). 2015. ↩︎
Vos et al. DJ-1 function (2010). 2010. ↩︎
Matsuda et al. PINK1 in mitophagy (2010). 2010. ↩︎
Narendra et al. Parkin in mitophagy (2008). 2008. ↩︎
Liu et al. SOD1 and mitochondria (2005). 2005. ↩︎
Crippa et al. C9orf72 and mitochondria (2016). 2016. ↩︎
Ryan et al. Motor neuron energy demands (2013). 2013. ↩︎
Shachtman et al. Axonal mitochondria in ALS (2012). 2012. ↩︎
Choo et al. Huntingtin and VDAC (2004). 2004. ↩︎
Cui et al. PGC-1α in HD (2006). 2006. ↩︎
Squitieri et al. ATP in HD (2009). 2009. ↩︎
Zhang et al. Cromakalim in HD (2013). 2013. ↩︎
Ferrer et al. CoQ10 in HD (2005). 2005. ↩︎
Lee et al. Cytochrome c as biomarker (2003). 2003. ↩︎
Mogi et al. mtDNA in CSF (2009). 2009. ↩︎
Beatrice et al. Caspase-3 in AD (2001). 2001. ↩︎
Boutagy and Byrne, Lactate/pyruvate in neurodegeneration (2005). 2005. ↩︎
Ono et al. PET mitochondrial imaging (2013). 2013. ↩︎